Long-Term Evaluation of BIIB067 (Tofersen)

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

August 12, 2024

Study Completion Date

August 12, 2024

Conditions
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Interventions
DRUG

Tofersen

Participants will receive a loading dose regimen followed by maintenance dosing.

Trial Locations (30)

2400

Bispebjerg Hospital, Copenhagen

3000

Research Site, Leuven

10126

Research Site, Torino

21287

Research Site, Baltimore

30322

Research Site, Atlanta

32224

Research Site, Jacksonville

32806

Research Site, Orlando

33136

Research Site, Miami

37920

Research Site, Knoxville

44106

Research Site, Cleveland

55905

Research Site, Rochester

60611

Research Site, Chicago

63003

Research Site, Clermont-Ferrand

63110

Research Site, St Louis

68510

Research Site, Lincoln

85013

Research Site, Phoenix

89081

Research Site, Ulm

94118

Research Site, San Francisco

97213

Research Site, Portland

92093-0949

Research Site, La Jolla

02114

Research Site, Boston

T2N 4Z6

Research Site, Calgary

T6G 2B7

Research Site, Edmonton

M4N 3M5

Research Site, Toronto

H3A2B4

Research Site, Montreal

Unknown

Research Site, Bunkyō City

Research Site, Kagoshima

Research Site, Shinjuku-ku

Research Site, Suita-shi

S102HQ

Research Site, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Biogen

INDUSTRY